Diabetic retinopathy affects nearly all young patients with type 1 diabetes

Article

One in three young Danish patients with type 1 diabetes mellitus progressed to proliferative diabetic retinopathy, and two in three had 2-step progression despite their young age, according to study results recently published in the November 2013 issue of Acta Diabetologica. In addition, these researchers from Denmark found that after 30-years? duration of diabetes, the presence of diabetic retinopathy was almost universal.

One in three young Danish patients with type 1 diabetes mellitus progressed to proliferative diabetic retinopathy, and two in three had 2-step progression despite their young age, according to study results recently published in Acta Diabetologica. In addition, these researchers from Denmark found that after 30-years' duration of diabetes, the presence of diabetic retinopathy was almost universal.

From 1987 to 1989, these researchers identified a paediatric cohort of children that included approximately 75% of all children in Denmark with type 1 diabetes

In 1995, mean patient age was 21.0 years, and mean duration of diabetes was 13.5 years. The 16-year incidence of proliferative retinopathy was 31.0%, 2-step progression was 64.4% and 2-step regression of diabetic retinopathy was 0.0%. The incidence of diabetic retinopathy was 95.1%.

Upon multivariate logistic regression modelling, progression to proliferative diabetic retinopathy was significantly associated with HbA1c levels in 1995 (OR: 2.61 per 1% increase, 95% CI: 1.85-3.68) and diastolic BP of 1995 (OR: 1.79 per 10 mmHg increase, 95% CI: 1.04-3.07). Two-step progression of diabetic retinopathy was associated with male gender (OR: 2.37 versus female, 95% CI: 1.07-5.27), 1995 HbA1c (OR: 3.02per 1% increase, 95% CI: 2.04-4.48), and 1995 vibration perception threshold (OR: 1.19 per 1 volt increase, 95% CI: 1.02-1.40).

To access these data, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.